Biomea Fusion (BMEA) Other financing activities (2021 - 2025)
Biomea Fusion (BMEA) posted Other financing activities of -$594000.0 for Q4 2025, down 193.4% sequentially from $636000.0 in Q3 2025, and down 135.61% YoY from $1.7 million in Q4 2024.
Biomea Fusion (BMEA) Other financing activities (2021 - 2025) Analysis & Trends
Biomea Fusion has reported Other financing activities for 5 years, with the latest figure at -$594000.0 in Q4 2025.
- Quarterly Other financing activities fell 135.61% year-over-year to -$594000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $159000.0 (down 90.47% YoY) and the FY2025 annual result came in at $159000.0, down 90.47% from the prior year.
- Other financing activities declined to -$594000.0 in Q4 2025 per BMEA's latest filing, from $636000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $152.5 million in Q3 2021 and troughed at -$152.3 million in Q4 2021.
- A 5-year average of $353600.0 and a median of $318000.0 in 2022 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2023 and 2025: Other financing activities surged 548.39% in 2023, then slumped 135.61% in 2025.
- Over 5 years, Other financing activities stood at -$152.3 million in 2021, then jumped by 100.32% to $490000.0 in 2022, then rose by 26.94% to $622000.0 in 2023, then jumped by 168.17% to $1.7 million in 2024, then plunged by 135.61% to -$594000.0 in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered -$594000.0, $636000.0, and $112000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -594,000.00 |
| Dec 31, 2025 | -594,000.00 |
| Sep 30, 2025 | 636,000.00 |
| Sep 30, 2025 | 636,000.00 |
| Jun 30, 2025 | 112,000.00 |
| Jun 30, 2025 | 112,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 1.67 Mn |
| Dec 31, 2024 | 1.67 Mn |
| Dec 31, 2023 | 622,000.00 |
| Dec 31, 2023 | 622,000.00 |
| Sep 30, 2023 | 138,000.00 |
| Sep 30, 2023 | 138,000.00 |
| Jun 30, 2023 | 1.03 Mn |
| Jun 30, 2023 | 1.03 Mn |
| Mar 31, 2023 | 201,000.00 |
| Mar 31, 2023 | 201,000.00 |
| Dec 31, 2022 | 490,000.00 |
| Dec 31, 2022 | 490,000.00 |